532
R. Kuwano et al. / Tetrahedron: Asymmetry 17 (2006) 521–535
4.14.3. (+)-3-(2-Propyl)-N-(p-toluenesulfonyl)indoline 4f
(Table 6, entry 1). The general procedure was followed
with the exception of amount of solvent (1 ml) and reac-
tion time (48 h), with 3-(2-propyl)-N-(p-toluenesulfon-
yl)indole 3f (157 mg, 0.50 mmol) to give 4f (152 mg,
50 ꢁC, UV 254 nm detection, (ꢀ) t1 = 54.1 min, (+)
t2 = 58.0 min.
4.14.6. (+)-3-[2-{N-(tert-Butoxycarbonyl)amino}ethyl]-
N-(p-toluenesulfonyl)indoline 4i (Table 6, entry 4).
The general procedure was followed with 3-[2-{N-(tert-
butoxycarbonyl)amino}ethyl]-N-(p-toluenesulfonyl)-
indole 3i (208 mg, 0.50 mmol) to give 4i (148 mg,
20
1
94%): colorless oil; ½aꢁD ¼ ꢀ19:1 (c 1.06, CHCl3); H
NMR (400 MHz, CDCl3, TMS) d 0.63 (d, J = 6.8 Hz,
3H), 0.88 (d, J = 6.8 Hz, 3H), 1.87 (double septet,
J = 4.8, 6.8 Hz, 1H), 2.37 (s, 3H), 3.11 (dt, J = 10.5,
5.2 Hz, 1H), 3.73 (dd, J = 5.5, 10.5 Hz, 1H), 3.81 (dd,
J = 10.0, 10.5 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 7.06
(d, J = 7.5 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.23 (d,
J = 8.0 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.71 (d,
J = 8.0 Hz, 2H); 13C {1H} NMR (100.5 MHz, CDCl3)
d 17.3, 20.0, 21.5, 31.3, 45.8, 51.7, 114.1, 123.2, 125.0,
127.3, 127.9, 129.6, 133.9 (2C), 142.2, 144.0; Anal. Calcd
for C18H21NO2S: C, 68.54; H, 6.71; N, 4.44. Found: C,
68.47; H, 6.70; N, 4.39. The enantiomeric excess of 4f
was determined to be 97% ee by HPLC analysis with
CHIRALCEL OD-H (4.6 mm B · 250 mm), 20% 2-
propanol in hexane, 0.5 ml/min flow, at 35 ꢁC, UV
254 nm detection, (+) t1 = 17.3 min, (ꢀ) t2 = 19.3 min.
20
1
71%): colorless solid; ½aꢁD ¼ þ9:0 (c 1.02, CHCl3); H
NMR (300 MHz, CDCl3, TMS) d 1.32–1.55 (m, 1H),
1.44 (s, 9H), 1.67–1.80 (m, 1H), 2.37 (s, 3H), 3.05–3.20
(m, 3H), 3.61 (dd, J = 5.9, 10.6 Hz, 1H), 4.00 (dd,
J = 9.2, 10.6 Hz, 1H), 4.48 (br s, 1H), 6.99 (t,
J = 7.4 Hz, 1H), 7.08 (d, J = 7.4 Hz, 1H), 7.17–7.26
(m, 3H), 7.65 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 8.4 Hz,
2H); 13C {1H} NMR (75 MHz, CDCl3) d 21.4, 28.3,
29.6, 35.3, 37.6, 38.2, 55.4, 114.9, 123.8, 124.4, 127.4,
128.2, 129.7, 133.9, 134.9, 141.7, 144.2, 155.9; Anal.
Calcd for C22H28N2O4S: C, 63.44; H, 6.78; N, 6.73.
Found: C, 63.71; H, 6.83; N, 6.60. The enantiomeric
excess of 4i was determined to be 95% ee by HPLC
analysis with CHIRALCEL OC (4.6 mm B ·
250 mm), 20% 2-propanol in hexane, 0.5 ml/min flow,
at 35 ꢁC, UV 254 nm detection, (+) t1 = 31.6 min, (ꢀ)
t2 = 38.8 min.
4.14.4. (+)-3-Phenyl-N-(p-toluenesulfonyl)indoline 4g
(Table 6, entry 2). The general procedure was followed
with 3-phenyl-N-(p-toluenesulfonyl)indole 3g (174 mg,
0.50 mmol), [Rh(nbd)2]SbF6 (5.2 mg, 10 lmol), and
4.14.7. tert-Butyl (+)-3-[N-(p-toluenesulfonyl)indolin-3-
yl]propionate 4j (Table 6, entry 5). The general proce-
dure was followed with tert-butyl 3-[N-(p-toluenesulfon-
(S,S)-(R,R)-PhTRAP (8.3 mg, 10.5 lmol) to give
25
4g (163 mg, 93%): colorless solid; ½aꢁD ¼ þ88:9 (c 1.01,
yl)indol-3-yl]propionate 3j (201 mg, 0.50 mmol) to
1
CHCl3); H NMR (400 MHz, CDCl3, TMS) d 2.39 (s,
20
give 4j (187 mg, 93%): colorless solid; ½aꢁD ¼ þ15:6 (c
3H), 3.74–3.82 (m, 1H), 4.31–4.38 (m, 2H), 6.84–6.89
(m, 3H), 6.97 (t, J = 7.5 Hz, 1H), 7.17–7.28 (m, 6H),
7.68 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 1H); 13C
{1H} NMR (100.5 MHz, CDCl3) d 21.6, 46.2, 58.5,
114.9, 124.0, 125.6, 127.1, 127.4, 127.7, 128.3, 128.7,
129.7, 133.8, 134.8, 142.1, 142.4, 144.1; Anal. Calcd
for C21H19NO2S: C, 72.18; H, 5.48; N, 4.01. Found:
C, 71.96; H, 5.46; N, 3.90. The enantiomeric excess of
4g was determined to be 96% ee by HPLC analysis with
CHIRALCEL OD-H (4.6 mm B · 25 cm): 20% 2-pro-
panol in hexane, 0.5 ml/min flow, at 35 ꢁC, UV
254 nm detection, (+) t1 = 26.4 min, (ꢀ) t2 = 31.6 min.
1.06, CHCl3); 1H NMR (300 MHz, CDCl3, TMS) d
1.43 (s, 9H), 1.47–1.60 (m, 1H), 1.79–1.92 (m, 1H),
2.16 (t, J = 7.7 Hz, 2H), 2.36 (s, 3H), 3.08–3.20 (m,
1H), 3.58 (dd, J = 5.9, 10.4 Hz, 1H), 3.97 (dd, J = 9.0,
10.4 Hz, 1H), 6.99 (dt, J = 0.9, 7.5 Hz, 1H), 7.09 (d,
J = 7.5 Hz, 1H), 7.18–7.26 (m, 3H), 7.65 (d,
J = 8.4 Hz, 1H), 7.69 (d, J = 8.1 Hz, 2H); 13C {1H}
NMR (75 MHz, CDCl3) d 21.4, 28.0, 29.7, 32.5, 39.0,
55.2, 80.6, 114.8, 123.7, 124.6, 127.3, 128.2, 129.7,
133.8, 134.7, 141.7, 144.2, 172.2; Anal. Calcd for
C22H27NO4S: C, 65.81; H, 6.78; N, 3.49. Found: C,
66.03; H, 6.82; N, 3.50. The enantiomeric excess of 4j
was determined to be 97% ee by HPLC analysis with
CHIRALPAK AD (4.6 mm B · 250 mm), 4% 2-propa-
nol in hexane, 0.5 ml/min flow, at 35 ꢁC, UV 254 nm
detection, (+) t1 = 37.7 min, (ꢀ) t2 = 41.6 min.
4.14.5.
(+)-3-[2-(tert-Butyldimethylsilyloxy)ethyl]-N-
(p-toluenesulfonyl)indoline 4h (Table 6, entry 3). The
general procedure was followed with 3-[2-(tert-butyl-
dimethylsilyloxy)ethyl]-N-(p-toluenesulfonyl)indole 3h
(215 mg, 0.50 mmol) to give 4h (202 mg, 94%): colorless
4.14.8. Methyl 3-[N-(p-toluenesulfonyl)indolin-3-yl]propi-
onate 4k (Table 6, entry 6). The general procedure was
followed with methyl 3-[N-(p-toluenesulfonyl)indol-3-
20
solid; ½aꢁD ¼ þ9:7 (c 1.18, CHCl3); 1H NMR (300 MHz,
CDCl3, TMS) d 0.05 (s, 6H), 0.90 (s, 9H), 1.32–1.45 (m,
1H), 1.70–1.82 (m, 1H), 2.32 (s, 3H), 3.14–3.27 (m, 1H),
3.57 (dd, J = 6.6, 10.8 Hz, 1H), 3.58 (t, J = 6.0 Hz, 2H),
3.99 (dd, J = 9.0, 10.8, 1H), 6.94 (dt, J = 0.8, 7.4 Hz,
1H), 7.02 (d, J = 7.4 Hz, 1H), 7.12–7.21 (m, 3H), 7.58–
7.66 (m, 3H); 13C {1H} NMR (75 MHz, CDCl3) d
ꢀ5.5, 18.1, 21.4, 25.8, 37.2, 37.5, 56.0, 60.7, 114.9,
123.7, 124.4, 127.4, 128.0, 129.7, 134.1, 135.7, 141.8,
144.0; Anal. Calcd for C23H33NO3SSi: C, 64.00; H,
7.71; N, 3.24. Found: C, 64.27; H, 7.86; N, 3.33. The
enantiomeric excess of 4h was determined to be 98%
ee by HPLC analysis with Ceramospher RU-1
(4.6 mm B · 250 mm), methanol, 0.08 ml/min flow, at
1
yl]propionate 3k (179 mg, 0.50 mmol). H NMR analy-
sis of the resulting reaction mixture indicated that 4k
was formed in 32%. The enantiomeric excess of 4k was
determined to be 97% ee by HPLC analysis with CHIR-
ALPAK AS (4.6 mm B · 250 mm), 30% 2-propanol in
hexane, 0.5 ml/min flow, at 35 ꢁC, UV 254 nm detection,
t1 = 23.3 min, t2 = 28.0 min.
4.14.9. tert-Butyl [N-(p-toluenesulfonyl)indolin-3-yl]ace-
tate 4l (Table 6, entry 7). The general procedure was
followed with tert-butyl [N-(p-toluenesulfonyl)indol-3-
1
yl]acetate 3l (98 mg, 0.25 mmol). H NMR analysis of